Logistics · Deep dive

Airspace

An AI-dispatched network of next-flight-out, on-board-courier and ground capacity that routes organs, aircraft-on-ground parts and semiconductor tooling across 30,000+ drivers and commercial airline belly space — a $138M-raised time-critical logistics platform that has not announced new capital since its May 2022 Series D.

emerging

The question that decides it: Airspace's dispatch algorithm is only as good as the commercial airline belly-space and courier capacity it arbitrages across — capacity it does not own. Can an independent, VC-funded orchestration layer keep out-executing vertically integrated incumbents (Kuehne+Nagel's Quick Group spanning both AOG aviation and clinical-trial logistics, UPS Healthcare's Marken/MNX, Cencora's World Courier) that own their own aircraft, couriers and cold-chain assets — for long enough to reach IPO-scale revenue as a standalone company? Or does capital-light routing technology without owned capacity get bundled into an incumbent's stack (or bought outright) before Airspace ever needs to answer that question on its own terms?

My take ★★ Very interesting ★ Interesting − Maybe ✗ Not interesting

Snapshot

Airspace is a Carlsbad, California-based logistics platform that routes time-critical shipments — organs and tissue for transplant, aircraft-on-ground (AOG) parts, semiconductor fab tooling, clinical trial samples, cell and gene therapies — across whichever combination of commercial airline belly space, next-flight-out (NFO) booking, on-board couriers, charter aircraft and ground courier gets the package there fastest. Founded in 2016 by Nick Bulcao and Ryan Rusnak, it has raised $138M across four venture rounds, most recently a $70M Series D in May 2022 led by early Tesla backer DBL Partners. The company claims an estimated $73.5M in annual revenue (Kona Equity, 2024-25 estimate), roughly 350-450 employees, a network of 30,000+ independent-contractor drivers and access to 2,500+ commercial aircraft, and a customer base that includes Qualcomm and roughly a third of the world’s 25 largest semiconductor companies. The single most important fact about Airspace’s position: it is a software-and-orchestration layer sitting on top of capacity — airline cargo holds, courier networks, ground fleets — that it does not own, competing against incumbents (Kuehne+Nagel, UPS Healthcare, Cencora) that increasingly do own theirs.

Founding story

Nick Bulcao did not arrive at time-critical logistics from a technology or medical background — he arrived from operating ground-transportation businesses. He owned and ran Sun Distributing and First Delivery, both critical-transportation operators, and built a last-mile delivery partnership with Amazon that spanned 11 West Coast locations, more than 600 employees and a reported $36M in annual revenue (Qualcomm Ventures Founder Spotlight). Running that business exposed him to the operational chaos underneath time-critical shipping: dispatchers working phones and spreadsheets, no unified visibility into where an urgent shipment actually was, and a fragmented industry of small regional operators with no shared technology layer. He concluded the opportunity was not another trucking company but the coordination software the whole category lacked, and founded Airspace in 2016.

Ryan Rusnak, who joined as co-founder and CTO, brought a very different background: a Master’s in Human-Computer Interaction from Carnegie Mellon, prior work building federal government software including an application used to construct the federal budget and the White House’s iOS app under the Obama administration, plus early machine-learning collaboration with the National Institutes of Health. The pairing mirrors a familiar logistics-tech formula — an operator who has lived the industry’s dysfunction, paired with an engineer capable of building the routing and visibility software to fix it — aimed at what the founders identified as the two core failures of critical logistics: lack of transparency and lack of speed.

How it works

The mechanics start with a shipment that cannot fail on timing: an organ that must reach a transplant center within a hard biological window, an aircraft grounded (AOG) at an airport waiting on a single part, a semiconductor fab that loses roughly $1M per hour of downtime without a replacement tool. A customer — a transplant coordinator, an airline MRO desk, a fab operations manager — requests a shipment through Airspace’s platform or a dispatcher, and the system generates an instant quote based on weight, dimensions, origin, destination and pickup urgency (company platform materials).

Airspace’s dispatch technology then evaluates routing options in real time: Next Flight Out (NFO) booking on commercial passenger or cargo belly space, an on-board courier who personally carries the shipment on a commercial flight, a chartered aircraft for shipments too large, sensitive or time-constrained for scheduled service, or a ground route via the company’s driver network for shorter distances or as a first/last-mile leg feeding an air movement. The company brands its independent-contractor driver network “Commanders” and “Copilots,” who use a dedicated Airspace Driver App for real-time GPS tracking and status updates, layered with IoT sensor data for cold-chain and dangerous-goods shipments. When a flight is delayed, cancelled or a driver hits traffic, the same system is meant to trigger contingency re-routing — rebooking the next available flight or driver — rather than leaving a human dispatcher to discover the problem after the fact. The proprietary network claims access to 30,000+ drivers and 2,500+ commercial aircraft, but critically, Airspace owns none of that capacity: it is an orchestration and booking layer over airline cargo holds, agent-partner networks and contracted couriers.

Product and business overview

Airspace organizes its offering around two axes: logistics services and industries served. The services are Next Flight Out (NFO), On-Demand Ground, Charter, On-Board Courier, Dangerous Goods handling, and Cold Chain — the full menu a time-critical shipper needs regardless of vertical (company site, “Solutions”).

The industry verticals are where the company’s positioning is sharpest. Aerospace & Defense covers AOG situations, parts supply, tooling and reverse logistics for OEMs, MROs and commercial/business aviation customers. Health Systems & Labs covers blood, lab samples, pharmaceuticals, hospital equipment and vaccines for hospitals and diagnostic labs. Life Sciences is the highest-stakes vertical: organs, tissue, IVF (human and animal), and cell and gene therapies, where a shipment delay is not a business cost but a clinical failure. Medical Devices covers surgical instruments, musculoskeletal devices and larger equipment like X-ray machines. High-Tech & Semiconductor, the newest major push (formalized with the March 2024 Southeast Asia expansion), covers machine-down MRO parts, fabrication tools, prototypes and sensitive goods for evaluation and testing. Manufacturing & Automotive rounds out the set with construction materials, robotics and inbound/outbound production shipments.

The organ-transplant business is a genuine proof point rather than a marketing claim: Airspace has partnered with the Southwest Transplant Alliance (STA) since 2018, and by the time of STA’s public case study the two organizations had coordinated more than 6,000 successful organ and tissue shipments together, including kidneys and pancreata. Airspace’s own marketing claims the company has “saved more than 100,000 lives” through time-critical medical shipments since inception — a company-sourced figure that should be read as directional rather than independently audited.

Business model and pricing

Airspace runs a pure per-shipment model — there is no subscription tier and no published rate card. Every shipment is quoted individually based on weight, dimensions, origin, destination, pickup urgency and any special handling requirements (dangerous goods, cold chain), with the company advertising an “instant quoting” capability that returns a spot rate in well under a minute rather than requiring a phone call. Revenue is booked as the gross margin between what the customer is charged and what Airspace pays the airline, charter operator, on-board courier or ground contractor actually moving the shipment — the same economics as a non-asset-based freight broker or forwarder, but concentrated in a niche where urgency, not volume, sets the price. Time-critical logistics carries materially higher gross margins than standard freight brokerage because the customer’s willingness to pay is set by the cost of failure (a lost organ, a grounded aircraft, a stalled fab line) rather than by competitive freight-rate benchmarking; industry participants in this category have historically reported gross margins in the 30-40% range on time-critical work, well above the high-single-digit to low-teens margins typical of commodity truckload brokerage. Airspace has not published its own margin figures, so this should be read as a category benchmark rather than a company-specific disclosure.

Traction over time

The pattern worth flagging: Airspace has not announced a funding round since the May 2022 Series D — more than four years as of this writing. That is a long gap for a company whose last disclosed valuation marker was an $80M pre-money figure from the 2018 Series B. Either the company has reached sufficient revenue and margin to fund growth internally, or it has been unable to raise a round at a valuation existing investors will accept — both are plausible, and the company has not clarified which.

Market analysis

The global time-critical logistics market was valued at roughly $18.7-21.8B in 2024 depending on the analyst, with forecasts converging around $42.5-47.5B by 2033 at a 9-10% CAGR (Growth Market Reports; MarketIntelo, 2024-25 estimates). Structural growth drivers include the expansion of cell and gene therapy manufacturing (each shipment is a live biological product with a hard clinical deadline), an aging commercial aircraft fleet driving more frequent AOG events, and a semiconductor industry where a single fab’s unplanned downtime can cost roughly $1M per hour, making expedited tooling and parts logistics a rounding-error expense against the alternative. Asia-Pacific is projected to post the fastest regional growth (12.4% CAGR, 2025-2033) on the back of semiconductor manufacturing concentration and cross-border trade growth — directly validating Airspace’s 2024 Southeast Asia expansion.

The organ-transplant sub-vertical carries its own distinct regulatory tailwind. The US Health Resources and Services Administration (HRSA) launched an Organ Procurement and Transplantation Network (OPTN) Modernization Initiative in March 2023, and Congress passed the Securing the U.S. Organ Procurement and Transplantation Network Act in fall 2023 — ending nearly 40 years in which a single vendor held the entire OPTN contract and shared a board with the network itself. HRSA is now issuing multiple, function-specific contracts (technology, data, operations) rather than one monopoly award, which structurally opens the door to more transportation- and logistics-specific vendors winning discrete pieces of the organ-transport chain rather than routing everything through one incumbent relationship. Separately, drone-based organ transport is moving from pilot to operational: Mid-America Transplant opened a 160-mile FAA-coordinated drone corridor in 2026 that cuts a three-hour ground transport to under two hours at roughly one-tenth the cost of traditional methods — an early signal that a meaningfully cheaper mode could erode the highest-margin, highest-urgency slice of Airspace’s life-sciences vertical over the next decade, starting with short-haul regional organ moves.

Competitive intel

Airspace’s honest competitive problem is that its most dangerous rivals are not other venture-backed platforms — they are divisions of giant, vertically integrated logistics and healthcare-distribution incumbents that own the capacity Airspace has to rent. Kuehne+Nagel’s Quick Group (acquired November 2018) is the sharpest example: it bundles Sterling Aviation (AOG/aviation logistics) with QuickSTAT and Quick Healthcare (clinical-trial and life-sciences logistics) inside one company that generated $200M+ net revenue at the time of acquisition — meaning a single incumbent already spans both of Airspace’s flagship verticals with owned global infrastructure. Marken, UPS Healthcare’s clinical-trial and advanced-therapy logistics arm (acquired 2016), operates in 220+ countries with about 4,000 staff moving 6.6M+ shipments a year, and absorbed MNX Global Logistics (UPS acquisition, 2021) into a single “Marken, UPS Healthcare Precision Logistics” brand by the mid-2020s — consolidation that signals UPS is building one owned, integrated time-critical healthcare network rather than buying software to orchestrate third-party capacity. World Courier, owned by Cencora (formerly AmerisourceBergen) since a $520M acquisition in 2012, gives one of the largest pharmaceutical distributors in the world its own cold-chain and clinical-trial logistics arm. Against all three, Airspace’s pitch is technology-first neutrality — it can route across any airline or courier rather than being limited to a parent company’s owned network — but that same independence means it has no owned capacity to fall back on when the market tightens, and every one of these incumbents can bundle time-critical logistics into a pharma-distribution or freight-forwarding relationship it already holds. Smaller independent Time Critical Solutions competes directly on price and speed without Airspace’s platform layer, and generalist forwarders like Flexport represent the risk that a much larger, better-capitalized logistics-tech company could bolt on a time-critical module.

History and evolution

• 2016 — Nick Bulcao and Ryan Rusnak found Airspace in Carlsbad, CA, after Bulcao’s prior ground-transportation and Amazon last-mile businesses exposed the lack of coordination technology in time-critical shipping.
• 2018 — Southwest Transplant Alliance partnership begins, marking Airspace’s entry into organ-transport logistics.
• 13 August 2018 — $8M Series A led by Defy, with Qualcomm Ventures, Cross Culture Ventures and Schematic Ventures.
• 15 November 2018 — $20M Series B led by Scale Venture Partners at an $80M pre-money valuation.
• 2019 — Named to CNBC’s Upstart 100 list.
• 26 January 2021 — $38M Series C.
• 6 April 2021 — Company announces expanded time-critical shipping services and highlights patented technology (BusinessWire).
• 16 April 2021 — Rebrands with a new visual identity and relaunched website as it broadens the industries it serves (BusinessWire).
• 25 May 2022 — $70M Series D led by DBL Partners, co-led by Telstra Ventures and HarbourVest Partners, bringing total funding to $138M; capital earmarked for global expansion (Europe, Asia) and sustainability initiatives, plus new service lines including expedited freight and new verticals (semiconductor, automotive, cleantech).
• 1 March 2024 — Announces Southeast Asia expansion, positioning itself as a leading critical-logistics provider for semiconductor supply chains; discloses Qualcomm Technologies as a customer and claims relationships with roughly a third of the world’s 25 largest semiconductor companies.
• 2024-2025 — No new funding round disclosed; competitor MNX is folded into the unified Marken/UPS Healthcare brand, consolidating two of Airspace’s rivals into one incumbent network.

What people say

The case for. Employee reviews on Glassdoor describe a genuine sense of mission uncommon in logistics: reviewers cite “great culture, a real community, and really challenging and fun work,” and describe the job as “very rewarding — helping people daily with life-saving, time-sensitive and expensive shipments” (Glassdoor, Airspace Technologies Reviews, 151 reviews). Investors have echoed the mission framing: Qualcomm Ventures’ founder profile of Bulcao and Rusnak frames the company as solving a life-or-death visibility problem the industry had simply tolerated for decades, and Scale Venture Partners’ investment writeup credits Airspace with being simultaneously “faster, cheaper and better” than the fragmented incumbents it displaced early on.

The complaints. The same Glassdoor review base surfaces a sharp internal fairness problem: several reviewers report that perks like unlimited PTO and flexible hours “don’t pertain to Operations Specialists,” who describe feeling treated worse than other departments and say the company does not live up to its own “one team” messaging. Other reviews describe a highly stressful environment with a toxic management culture in pockets of the organization, and the broader theme across reviews is a fast-paced startup that requires employees to “wear multiple hats” — a structure some find energizing and others find unsustainable, particularly in 24/7 operations roles where a missed dispatch has clinical or aviation-safety consequences. That operational pressure is a structural feature of the category, not a fixable culture problem: a company whose core product promise is never missing a deadline for an organ or a grounded aircraft is going to run its operations desk hot by design.

Outlook: the open question

Airspace’s bull case rests on a straightforward idea: routing intelligence that dynamically arbitrages across every mode (belly space, charter, on-board courier, ground) should beat any single incumbent’s owned, mode-limited network on speed and cost, and that edge should compound as more shipment history feeds better dispatch decisions. The evidence for this is real — a decade of survival and growth against much larger rivals, a genuine proprietary customer base (STA in organs, Qualcomm and other top-25 semiconductor names in high-tech), and category revenue growth (9-10% CAGR industry-wide) that gives a well-run platform room to take share.

The bear case is that Airspace does not own the thing that actually constrains time-critical logistics: capacity. Commercial airline belly space is a shrinking, increasingly optimized commodity as airlines themselves get better at yield-managing cargo holds, meaning the arbitrage opportunity Airspace’s algorithm exploits could compress over time rather than expand. Meanwhile its most direct competitors — Kuehne+Nagel’s Quick Group, UPS Healthcare’s Marken/MNX, Cencora’s World Courier — are consolidating owned aircraft, couriers and cold-chain infrastructure into single incumbent networks, and each has the balance sheet to either underprice Airspace on a given lane or simply build (or buy) equivalent routing software layered on top of capacity it already owns. The four-plus-year gap since Airspace’s last disclosed funding round is the single most important open data point: it either means the company has reached self-sustaining scale, or it means the growth-equity market has not been willing to fund another round at a step-up valuation.

What would confirm the bull case: a disclosed, audited revenue figure meaningfully above the current ~$73.5M estimate, expansion of the organ-transplant relationship model (STA-style exclusive OPO partnerships) into a majority of US organ procurement organizations, and a semiconductor-vertical revenue base that scales with fab openings in the US, Southeast Asia and Europe without requiring Airspace to take on owned aircraft. What would confirm the bear case: continued silence on new funding rounds combined with visible margin compression as airlines price belly space more aggressively, loss of marquee accounts to Marken/Quick Group’s bundled healthcare-and-aviation offering, or — the cleanest resolution — an acquisition by UPS, DHL, Cencora or Kuehne+Nagel that folds Airspace’s routing technology into an incumbent’s owned network rather than letting the standalone story play out to an IPO.

How to attack it

Do not attack Airspace by building a broader time-critical logistics platform — that fight requires matching its decade of airline and courier relationships and its existing customer base, and a well-funded incumbent (Quick Group, Marken) already does it with owned capacity Airspace lacks. Attack a single vertical deep enough that owning the last mile of relationships matters more than breadth.

Wedge 1: An organ-transplant-only network with direct OPO integrations. HRSA’s OPTN Modernization Initiative (2023-ongoing) is breaking apart a 40-year single-vendor monopoly and opening multiple, function-specific contracts — precisely the moment a specialist could win exclusive logistics relationships with individual Organ Procurement Organizations the way Airspace won Southwest Transplant Alliance, but at national scale and purpose-built around OPTN’s new data and transparency requirements rather than bolted onto a general logistics platform.

Wedge 2: Short-haul drone displacement of the highest-margin organ and blood-sample moves. Mid-America Transplant’s 160-mile FAA-coordinated drone corridor (2026) already demonstrates sub-two-hour transport at roughly one-tenth the cost of ground transport for regional distances. A drone-logistics specialist focused purely on organ and time-critical medical-sample transport within FAA-approved corridors could take the shortest, most price-insensitive segment of Airspace’s life-sciences vertical without ever needing an NFO booking or airline relationship at all.

Enumerated weaknesses a well-funded attacker could exploit. (i) Airspace owns no aircraft, couriers or ground fleet — every dollar of margin is exposed to capacity-owner pricing power, and airlines are getting better at yield-managing the exact belly space Airspace depends on. (ii) No disclosed funding round since May 2022 suggests either a valuation ceiling or a deliberate pause — either way, a well-capitalized new entrant can outspend on customer acquisition in a specific vertical. (iii) Employee reviews describe uneven treatment of Operations Specialists and stress-driven turnover in the 24/7 dispatch function — the exact roles where dispatch quality determines whether an organ arrives on time, making this an operational, not just cultural, vulnerability. (iv) Airspace’s temperature-controlled and specialized-device logistics rely on partners like Paragonix for organ preservation devices rather than owned technology, leaving a gap a vertically integrated device-plus-logistics competitor could close. (v) The semiconductor vertical is new (formalized March 2024) and unproven against Quick Group and Marken’s decades of pharma/aviation-specific trust — a fab-logistics specialist with direct foundry relationships could contest it before Airspace establishes the same depth.

Adjacent-segment play

The most defensible adjacent play is selling the routing engine itself as software rather than continuing to operate purely as a service provider. Airspace’s dispatch algorithm — which arbitrages across NFO, charter, on-board courier and ground capacity in real time — is a genuinely hard technical asset. Packaged as a SaaS routing layer sold to smaller regional expediters, freight brokers and even hospital logistics departments that cannot build this technology themselves, it would compete with route-optimization players like FourKites and project44 but purpose-built for the 24-hour urgent segment those platforms do not specialize in. This inverts Airspace’s current cost structure — from capacity-arbitrage margin to recurring software revenue — and would generate a defensible moat instead of one that decays as airlines optimize their own cargo yield.

A second adjacent segment is diplomatic, legal and high-value courier logistics — time-critical shipments of sealed legal documents, election materials, fine art and jewelry share the exact operational profile (NFO booking, on-board courier, chain-of-custody tracking) Airspace already runs for organs and AOG parts, just with a different customer base and higher price tolerance. No dominant venture-backed player currently owns this niche the way Airspace owns life-sciences and AOG.

A third, weaker adjacent is luxury retail last-mile, but this segment is already dominated by specialists like Fabric and traditional white-glove delivery networks with retail-specific integrations Airspace does not have, and the urgency profile (same-day retail delivery) is fundamentally less extreme than organ transport or AOG — the wedge does not generalize as cleanly, because the customer’s willingness to pay for speed collapses once the shipment is a handbag rather than a kidney.

Sources and further reading

• Airspace Announces $70 Million Round Of Funding Focused On Global Expansion & Sustainability — PR Newswire, 25 May 2022.
• Early Tesla investor DBL Partners leads $70 million investment in logistics firm Airspace — CNBC, 25 May 2022.
• Airspace Technologies Raises $8 Million Series A Led by Defy — PR Newswire, 13 August 2018.
• Founder Spotlight: Airspace’s Nick Bulcao and Ryan Rusnak on Using AI to Transform Logistics — Qualcomm Ventures.
• Airspace Technologies: Faster, Cheaper, Better Time-Sensitive Deliveries — Scale Venture Partners.
• Airspace Expands Presence in Asia and Emerges as the Leading Critical Logistics Provider Tackling Semiconductor Supply Chain Issues — PR Newswire, 1 March 2024.
• STA and Airspace Track Critical Shipments to Deliver Second Chances at Life — Southwest Transplant Alliance.
• Kuehne + Nagel acquires a global market leader in time-critical shipments — Kuehne+Nagel Newsroom, November 2018.
• UPS to Acquire MNX in Strategic Move to Expand Global Healthcare and Time-Critical Capabilities — UPS, 2021.
• Airspace Technologies: $73.5M Revenue, Employees & Growth — Kona Equity, 2024-25 estimate.
• Airspace Reviews (151) — Glassdoor — Glassdoor.
• HRSA Announces Organ Procurement and Transplantation Network Modernization Initiative — HRSA, 2023-2024.
• Mid-America Transplant Opens 160-Mile Drone Corridor for Organ Donation — DroneLife, April 2026.